A. Amelsberg

1.5k total citations
22 papers, 852 citations indexed

About

A. Amelsberg is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, A. Amelsberg has authored 22 papers receiving a total of 852 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in A. Amelsberg's work include HER2/EGFR in Cancer Research (9 papers), Lung Cancer Treatments and Mutations (7 papers) and Colorectal Cancer Treatments and Studies (5 papers). A. Amelsberg is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Lung Cancer Treatments and Mutations (7 papers) and Colorectal Cancer Treatments and Studies (5 papers). A. Amelsberg collaborates with scholars based in United States, Germany and Netherlands. A. Amelsberg's co-authors include P. Tanswell, Ralf‐Dieter Hofheinz, Peter Stopfer, G. Hartung, Hartmut Kuthan, C. Renner, Holger Huisman, G. Stehle, Salah‐Eddin Al‐Batran and Ulrich Kunz and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Hepatology.

In The Last Decade

A. Amelsberg

22 papers receiving 836 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Amelsberg United States	13	619	301	262	131	117	22	852
J. L. Formento France	12	481 0.8×	306 1.0×	231 0.9×	142 1.1×	93 0.8×	19	851
Hisao Fukumoto Japan	17	432 0.7×	587 2.0×	193 0.7×	129 1.0×	71 0.6×	30	1.0k
Isabelle Hennebelle France	19	726 1.2×	506 1.7×	188 0.7×	106 0.8×	91 0.8×	25	1.1k
B. F. El-Rayes United States	19	615 1.0×	348 1.2×	385 1.5×	220 1.7×	166 1.4×	38	1.2k
Hirokazu Kurokawa Japan	13	555 0.9×	511 1.7×	105 0.4×	154 1.2×	43 0.4×	29	913
Amy Weise United States	19	530 0.9×	438 1.5×	259 1.0×	102 0.8×	43 0.4×	69	946
Su Cheol Park South Korea	19	300 0.5×	224 0.7×	357 1.4×	217 1.7×	288 2.5×	30	1.2k
Philip Bonomi United States	15	593 1.0×	592 2.0×	403 1.5×	120 0.9×	67 0.6×	37	1.2k
Jon Burrows United States	9	429 0.7×	674 2.2×	238 0.9×	134 1.0×	113 1.0×	20	1.1k
Hitoyasu Futami Japan	16	420 0.7×	330 1.1×	115 0.4×	89 0.7×	115 1.0×	41	869

Countries citing papers authored by A. Amelsberg

Since Specialization

Citations

This map shows the geographic impact of A. Amelsberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Amelsberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Amelsberg more than expected).

Fields of papers citing papers by A. Amelsberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Amelsberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Amelsberg. The network helps show where A. Amelsberg may publish in the future.

Co-authorship network of co-authors of A. Amelsberg

This figure shows the co-authorship network connecting the top 25 collaborators of A. Amelsberg. A scholar is included among the top collaborators of A. Amelsberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Amelsberg. A. Amelsberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Penson, David F., Andrew Armstrong, Raoul S. Concepcion, et al.. (2015). PII-LBA10 A MULTICENTER PHASE 2 STUDY OF ENZALUTAMIDE (ENZA) VERSUS BICALUTAMIDE (BIC) IN MEN WITH NONMETASTATIC (M0) OR METASTATIC (M1) CASTRATION-RESISTANT PROSTATE CANCER (CRPC): THE STRIVE TRIAL. The Journal of Urology. 193(4S). 5 indexed citations

Attard, G., et al.. (2015). 2537 Preliminary findings from PLATO: A two-period, phase 4, randomized, double-blind, placebo-controlled study of continued enzalutamide treatment beyond progression in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). European Journal of Cancer. 51. S487–S487. 2 indexed citations

Eskens, F., Constantijne H. Mom, André Planting, et al.. (2007). A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. British Journal of Cancer. 98(1). 80–85. 202 indexed citations

Solca, Flavio, et al.. (2006). 567 POSTER Efficacy of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in combination with cytotoxic agents. European Journal of Cancer Supplements. 4(12). 172–172. 15 indexed citations

Lewis, Nicole, et al.. (2006). A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors. Journal of Clinical Oncology. 24(18_suppl). 3091–3091. 18 indexed citations

Mom, Constantijne H., Ferry A.L.M. Eskens, Jourik A. Gietema, et al.. (2006). Phase 1 study with BIBW 2992, an irreversible dual tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) in a 2 week on 2 week off schedule. Journal of Clinical Oncology. 24(18_suppl). 3025–3025. 9 indexed citations

Shaw, Heather, Ruth Plummer, Rebecca M. Perrett, et al.. (2006). A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours. Journal of Clinical Oncology. 24(18_suppl). 3027–3027. 19 indexed citations

Stopfer, Peter, A. Amelsberg, Holger Huisman, et al.. (2005). Pharmacokinetic results from two phase I dose escalation studies of once daily oral treatment with BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.. Data Archiving and Networked Services (DANS). 6 indexed citations

Kloft, Charlotte, P. Tanswell, Andrew M. Scott, et al.. (2003). Population Pharmacokinetics of Sibrotuzumab, A Novel Therapeutic Monoclonal Antibody, in Cancer Patients. Investigational New Drugs. 22(1). 39–52. 47 indexed citations

10.

Hofheinz, Ralf‐Dieter, Salah‐Eddin Al‐Batran, Frank Hartmann, et al.. (2003). Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal Cancer. Oncology Research and Treatment. 26(1). 44–48. 289 indexed citations

11.

Greim, G., Markus Borner, K. Weigang-Köhler, et al.. (2002). Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. European Journal of Cancer. 38(8). 1072–1080. 57 indexed citations

12.

Amelsberg, A., et al.. (1999). Evidence for an anion exchange mechanism for uptake of conjugated bile acid from the rat jejunum. American Journal of Physiology-Gastrointestinal and Liver Physiology. 276(3). G737–G742. 20 indexed citations

13.

Hofmann, Alan F., A. Amelsberg, Claudio D. Schteingart, et al.. (1997). Successful Topical Dissolution of Cholesterol Gallbladder Stones Using Ethyl Propionate. Digestive Diseases and Sciences. 42(6). 1274–1282. 3 indexed citations

14.

Amelsberg, A., et al.. (1997). [Complications in endoscopic papillotomy].. PubMed. 35(12). 1111–4. 2 indexed citations

15.

Amelsberg, A., C D Schteingart, Jürgen M. Stein, et al.. (1997). Intestinal absorption of sodium dodecyl sulfate in the rodent: evidence for paracellular absorption. American Journal of Physiology-Gastrointestinal and Liver Physiology. 272(3). G498–G506. 9 indexed citations

16.

Amelsberg, A., et al.. (1996). Carrier-mediated jejunal absorption of conjugated bile acids in the guinea pig. Gastroenterology. 110(4). 1098–1106. 43 indexed citations

17.

Amelsberg, A., et al.. (1996). Cyclic Adenosine-3′,5′-Monophosphate Production Is Greater in Rabbit Duodenal Crypt Than in Villus Cells. Scandinavian Journal of Gastroenterology. 31(3). 233–239. 14 indexed citations

18.

McCashland, Timothy M., Jeremiah P. Donovan, A. Amelsberg, et al.. (1994). Bile acid metabolism and biliary secretion in patients receiving orthotopic liver transplants: Differing effects of cyclosporine and FK 506†. Hepatology. 19(6). 1381–1389. 30 indexed citations

19.

Amelsberg, A.. (1993). Contact dissolution of cholesterol gallstones with ethyl propionate (EP): Further clinical experience. Hepatology. 18(4). A98–A98. 2 indexed citations

20.

Amelsberg, A., et al.. (1992). Influence of heparin treatment on biochemical markers of an activation of the coagulation system. Thrombosis Research. 66(2-3). 121–131. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact